March 1st at 14:00 – 15:00
Virtual event
Flyer

Heikki Hyöty, Tampere University: “Type 1 diabetes, enterovirus and prospects of vaccine development”

Registration latest Feb 28 at: https://link.webropolsurveys.com/S/64C9EC43374D8B69
Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience. For further information contact Anne Lahdenperä (ankahy@utu.fi) or Riitta Lahesmaa (rilahes@utu.fi), University of Turku.

Dr. Heikki Hyöty is Professor of Virology at Tampere University, Faculty of Medicine and Health Technology since 2013. Prof. Hyöty has received his PhD in virology in 1989. He has served as Professor of Biomedicine and Virology at University of Tampere prior to his current position. Prof. Hyöty leads a virology group that studies the role of viruses and other microbes in immune-mediated diseases including type 1 diabetes, asthma, allergy and celiac disease. The group has studied  microbe-disease associations in prospective cohorts and translated innovations to develop new treatments and better diagnostics. One major initiative is the project developing an enterovirus vaccine that could prevent severe enterovirus diseases and type 1 diabetes. This project has generated a vaccine against Coxsackie B viruses which have been linked to type 1 diabetes.
Professor Hyöty is coordinator of four EU funded projects, and has 422 original articles and altogether nine patents/patent applications.

Selected publications:

1. Sioofy-Khojine AB, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala H,  Pakkanen O, Ruokoranta T, Hankaniemi MM, Toppari J, Vähä-Mäkilä M, Ilonen J, Veijola R, Knip M, Hyöty H. Coxsackievirus B infections are associated with the initiation of insulin-driven autoimmunity that progress to type 1 diabetes. Diabetologia 6:1193-1202, 2018.
2. Hyöty H, Leon F, Knip M. Developing a vaccine for Type 1 diabetes by targeting coxsackievirus B. Expert Rev Vaccines. 17(12):1071-1083, 2018.
3. Vehik K, Lynch KF, Wong MC, Tian X, Ross MC, Gibbs RA, Ajami NJ, Petrosino JF,  Rewers M, Toppari J, Ziegler AG, She JX, Lernmark A, Akolkar B, Hagopian WA, Schatz DA, Krischer JP, Hyöty H, Lloyd RE, and the TEDDY Study Group. Prospective virome analyses reveals prolonged enterovirus B shedding precedes islet autoimmunity in children at increased genetic risk for type 1 diabetes. Nat Med. 25(12):1865-1872, 2019.
4. Stone VM, Butrym M, Hankaniemi MM, Sioofy-Khojine A-B, Hytönen VP, Hyöty H, Flodström-Tullberg M. Coxsackievirus B vaccines prevent infection-accelerated diabetes in NOD mice and have no disease-inducing effect. Diabetes 70(12):2871-2878, 2021.
5. Oikarinen S, Krogvold L, Edwin B, Buanes T, Korsgren O, Laiho JE, Oikarinen M, Ludvigsson J, Skog O, Anagandula M, Frisk G, Hyöty H*, Dahl-Jørgensen K*. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64(11):2491-2501, 2021.